Skip to main content
. 2022 Sep 16;98(2):238–248. doi: 10.1111/cen.14812

Figure 2.

Figure 2

(A) Respondents' reports of prevalence (n = 239) and trend (n = 238) in patients experiencing persistent hypothyroid symptoms despite LT4 treatment returning serum TSH concentration to the reference interval. (B) Current prescribing practice, by age of respondent (n stated separately for each age group). (C) Willingness to consider prescribing combined LT4 + LT3 therapy in specified circumstances (n = 241).